The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guérin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Eisai; EnGeneIC; FerGene; Imagin Medical; Janssen; Medac; Merck; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FerGene; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Photocure; Seagen; SWOG; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Shahrokh Shariat
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cepheid; Ferring; Ipsen; Janssen; Lilly; Movember Foundation; MSD; Olympus; Pfizer; Pierre Fabre; Richard Wolf; Roche; Sanochemia; Sanofi; Takeda; UroGen pharma
Patents, Royalties, Other Intellectual Property - Method to determine prognosis after therapy for bladder cancer: 2003-06-19; Method to determine prognosis after therapy for prostate cancer: 2002-09-06; Prognostic methods for patients with prostatic cancer: 2004-08-05; Soluble FAS urinary marker for the detection of bladder transitional cell carcinoma: 2010-07-20
 
Gary D. Steinberg
Stock and Other Ownership Interests - Epivax Therapeutics; Urogen pharma
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; photocure; Roche/Genentech; Taris BioMedical
 
Shaheen Riadh Alanee
Leadership - IncellDx
Stock and Other Ownership Interests - IncellDx
Consulting or Advisory Role - AstraZeneca; IncellDx; Merck
Speakers' Bureau - AstraZeneca
Research Funding - Merck
 
Hiroyuki Nishiyama
Honoraria - MSD
Consulting or Advisory Role - Bayer; Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD
Speakers' Bureau - Chugai Pharma; MSD; Olympus
Research Funding - Astellas Pharma (Inst); Bayer; Ono Pharmaceutical (Inst); Takeda (Inst)
 
Kijoeng Nam
Employment - Merck
 
Ekta Kapadia
Employment - Merck
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar
 
Noah M. Hahn
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)